Is Inhaled Furosemide a Potential Therapeutic for COVID-19?

Content Provider	Europe PMC
Author	Brennecke, Anja Villar, Laura Wang, Zhiyu Doyle, Lisa M. Meek, Autumn Reed, Mark Barden, Christopher Weaver, Donald F.
Copyright Year	2020
Abstract	The potentially lethal infection caused by the novel Severe Acute Respiratory Disease Coronavirus-2 (SARS-CoV-2) has evolved into a global crisis. Following the initial viral infection is the host inflammatory response that frequently results in excessive secretion of inflammatory cytokines (e.g., IL-6 and TNFα), developing into a self-targeting, toxic “cytokine storm” causing critical pulmonary tissue damage. The need for a therapeutic that is available immediately is growing daily but the de novo development of a vaccine may take years. Therefore, repurposing of approved drugs offers a promising approach to address this urgent need. Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFα, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries. Furosemide is a “repurpose-able” small molecule therapeutics, that is safe, easily synthesized, handled, and stored, and is available in reasonable quantities worldwide.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7833957&blobtype=pdf
ISSN	00029629
Journal	The American Journal of the Medical Sciences [Am J Med Sci]
Volume Number	360
DOI	10.1016/j.amjms.2020.05.044
PubMed Central reference number	PMC7833957
Issue Number	3
PubMed reference number	32622469
e-ISSN	15382990
Language	English
Publisher	Southern Society for Clinical Investigation. Published by Elsevier Inc.
Publisher Date	2020-06-01
Access Restriction	Open
Rights License	Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
Subject Keyword	COVID-19 SARS-CoV-2 Furosemide Cytokine storm IL-6
Content Type	Text
Resource Type	Article
Subject	Medicine